The present invention relates to novel nitrosated and nitrosylated derivatives of 2,3-dihydro-lH-pyrrolizin moiety, preferably 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2, 3-dihydro-lH-pyrrolizin-5-yl -acetic acid, or their tautomeric forms, analogues, isomers, polymorphs, solvates, or pharmaceutically acceptable sal...

The present invention is related to a novel process of synthesis of 5-[[(2R,3S)-2-[(lR)-l-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyi]methyl]-l,2dihydro-3H-l,2,4-triazol-3-one  . (Aprepitant)  and  3-{[(2R53S)-2-[(lR)-l-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin...

A process for the preparation of a synergestic anti-spasmodic composition to be used as injection which comprises distilling Benzyl alcohol as pain reducer and dissolving it in a solvent propylene glycol, separately dissolving Diclofenac or its salts, in water, mixing the said pain reducer solution with the Diclo...

A novel composition to stabilize pharmaceutically active chemical/biological agents which are unstable even in solid state is provided which comprises the active chemical/biological agents along with polyhydric alcohols or their derivatives as a stabilizer in a ratio of from 100: 0.1 to 0.1: 100 w/w. ...

The present invention discloses a therapeutic composition for administration through inhalation route comprising nimesulide from 0.1% to 98% w/w in micro-particulate form, along with one or more excipients selected from the group comprising propellant, surfactant, stabilizing agent, wetting agent, solubilizer, antic...

The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk which has two compartments; the compartments consist of at least one active agent and at least one mucoadhesive agent and b...

A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient; at least one diluent; at least one binder, and a polymer system c...

A homogenous substantially alcohol free composition of Cyclosporin which comprises Cyclosporine A from 1-25% w/w in a hydrophilic carrier medium comprising propylene glycol from 0.5 - 70% w/w, esters of propylene glycol with C4 to C12 fatty acids from 15 -60% w/w and polyoxyethylene hydrogenated castor oils from 5 -...

Novel buccal dosage form compositions, preferably of poorly bioavailable drug(s), or drug(s) which undergo extensive presystemic metabolism, is provided. The compositions provide extended release of the drug in the oral cavity, and are preferably in the taste masked form. Process of preparation of such compositions ...

NA

Novel compositions and a method for treating anorectal diseases including hemorrhoids and colonic diseases with long term effectiveness and a low prolapse rate are disclosed. The compositions can be orally administered as well as uniformly applied to the affected region. The composition comprise of flavonoidal and p...

The present invention relates to the the process of preparation of polio vaccine. Provided is a Polio vaccine derived from Sabin strain for immunization against Poliomyelitis characterized in that the Polio Vaccine prepared is stabilized by adding a stabilizer and then inactivated by adding Formaldehyde (Formalin). ...

Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled...

The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hy...

The present invention is related to the field of synthetic chemistry. The present invention specifically relates to a process for the preparation of a crosslinked polyallylamine polymer, specifically carbonate salt of amine polymers, preferably Poly(allylamine-co-N,N'-diallyl-l,3-diamino-2-hydroxypropane)carbonate ,...

The present invention is related to a novel process of synthesis of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7. 10-dimethoxy-9-oxo-5,20-epoxytax-ll-en-2-yl benzoate (Cabazitaxel) and its pharmaceutic ally acceptable salts. ...

The present invention provides an improved process for the synthesis of indoline intermediate and its pharmaceutically acceptable derivatives, salts or solvates thereof, useful in the synthesis of α-1 adrenoceptor blockers such as silodosin.

The present invention relates to lyophilized pharmaceutical compositions for the treatment of various disease states, especially neoplastic diseases and autoimmune diseases. Particularly, it relates to pharmaceutical formulations comprising nitrogen mustards, particularly the nitrogen mustard bendamustine, e.g., ben...

The invention relates to improvement of culture and fermentation conditions for propagation and production of biomass and capsular polysaccharides by Streptococcus pneumoniae. The invention in particular relates to a novel culture medium free of serum and animal component for production of biomass and polysaccharide...

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically ...

The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabili...

The present invention is related to an improved process and intermediate(s) for the synthesis of beta amino acid derivatives of formula I. The compounds of formula I act as DPP-IV inhibitors and are useful in the treatment of Type 2 diabetes.

The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabal...

IMPROVED ORAL FAST DISSOLVING FILMS COMPRISING COMBINATION OF POLYMERS AND METHOD OF PREPARATION THEREOF The invention relates to an oral film having reduced adherence to oral cavity comprising water-soluble polymer as an essential polymer base in combination with film former, wherein the ratio of water-soluble pol...

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acce...

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmace...

The present invention relates to a novel process for purification of polysaccharide from Streptococcus pneumonia. The invention in particular relates to the process of purification comprising not more than 2 alcohol precipitating steps. The polysaccharide obtained by the process of the invention may be used for p...

Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form...

Topical pharmaceutical compositions comprising dry extract of Euphorbia species or drug or active agent with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistu...

The present invention relates to novel modified release compositions comprising at least one water soluble active agent(s) or its salts, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms, derivatives or mixtures thereof; a release controlling system comprising of at least one polymer(s) exhibi...

AAAAA

AAAAA

NA

The present invention provides a process for crystallization of various forms of silodosin. In particular the present invention provides a process for crystallizing a and P forms of silodosin from various solvents and their mixtures using various crystallization techniques.

A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or deriva...

A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and ezetimibe, its salts, analogs or derivatives thereof opti...

NA

The present invention relates to multilayered antidiabetic pharmaceutical compositions comprising at least two antidiabetic agents each selected from same or different classes of antidiabetic agents, at least one release rate controlling polymer(s) that predominantly controls the release of at least one antidiabetic...

The present invention relates to multilayered antidiabetic pharmaceutical compositions comprising a combination of atleast two antidiabetic agents, or their pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof as active agents, optionally with one or mo...

The invention describes a modified release oral dosage form of desmopressin which upon administration releases two or more amounts of desmopressin. The dosage form comprises of individual dosage units, such as an immediate release dosage unit and one or more delayed release dosage units, each comprising of a suitabl...

The present invention relates lo a stable pharmaceutical formulation comprising lanthanum carbonate and a pharmaceutical ly acceptable carrier. The present invention further relates to process for the preparation of pharmaceutical formulation comprising lanthanum carbonate. The present invention further relates lo t...

Novel pharmaceutical compositions comprising at least one active agent(s) or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one permeation enhancer(s); at least one adsorbent(s) and at least one bioadhesive polymer(s); opt...

Controlled release compositions comprising microparticles which comprise a core and at least one coat, wherein the core comprises at least one active agent(s), optionally at least one water insoluble polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at l...

The present invention relates to novel phenyl oxazolidinone compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of ...

Compositions comprising a combination of diclofenac and paracetamol, or pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof as active agents, optionally in association with one or more pharmaceutically acceptable excipient(s) are provided whereby parac...

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of ...

Compositions and process for preparation of such compositions comprising an extract of the plant Euphorbia prostrata useful particularly for the management of chronic venous insufficiency particularly varicose veins are provided. The compositions possess properties to control inflammation, prevent capillary bleeding...

Novel water soluble amino acid salts of 1H-1-benzazepine-1-acetic acid, process of preparation of such novel salts and methods of using them are provided. Also provided are pharmaceutical compositions comprising such novel salts and method of using such compositions for the prophylaxis, amelioration and/or treatment...

Novel pharmaceutical compositions comprising at least one poorly soluble active agent preferably a PDE4 inhibitor, at least one carrier(s) present in an amount not less than about 10% by weight of the composition, at least one hydrophilic component(s), optionally a solvent and optionally one or more other pharmaceut...

Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as...

Novel injectable compositions comprising at least one poorly soluble active agent(s), at least one surfactant(s), at least one oil component, and optionally other pharmaceutically acceptable excipient(s) is provided. The composition may be mixed with an aqueous component and optionally further diluted with a suitabl...

Novel sustained release pharmaceutical compositions comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system, and optionally other pharmaceutically acceptable excipients are provided. The present invention also describes process for preparation of su...

Novel sulfonanilide derivatives, preferably derivatives of N-(4-Nitro-2-phenoxy-phenyl)methane-sulfonamide, and their pharmaceutically acceptable salts, esters, amides, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof are provided. Also provided are process of preparation ...

Novel compositions for hair loss prevention and/or hair growth promotion comprising at least active agent preferably derived from natural source such as from the plant Vernonia sp., either alone or in combination with other active agent(s) and optionally one or more excipient(s) are provided. The process for the ext...

Novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvents, prodrugs or salts thereof as active ingredient su...

NOVEL PHARMACEUTICAL COMPOSITIONS AND PROCESS OF PREPARATION THEREOF"

Novel nitrosated and nitrosylated derivatives of IH-l-benzazepine-l-acetic acid, process of preparation of such novel derivatives and methods of using them are provided. Also provided are pharmaceutical compositions comprising such novel derivatives and method of using such novel compositions for the prophylaxi...

The present invention relates to anthrax recombinant fusion proteins process of preparation of such proteins and compositions thereof Particularly the recombinant fusion proteins of the present invention comprise a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor prote...

Provided in the present invention is an improved, efficient and commercially viable process for the preparation of (22R)-pregna-l,4-diene-3,20-dione-16,17-[(cyclohexylmethylene)bis(oxy)]- ll-hydroxy-21-(2-methyl-l-oxopropoxy) (l1ß, 16α) of Formula-1 as herein described using cheaper and non-hazardous chemicals th...

Provided in the present invention are improved oral pharmaceutical compositions comprising at least one poorly water soluble active agent, preferably endothelin conversion enzyme (ECE) inhibitor and/or neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, more preferably the act...

The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating can...

Novel amino acid salts of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-lH-pyrrolizin-5-yl-acetic acid or derivatives thereof, process for preparation of such salts and methods of using them are provided. Also provided are pharmaceutical compositions comprising such novel salts and methods of using such compo...

Pharmaceutical compositions comprising at least one endothelin conversion enzyme (ECE) inhibitor and/or neutral endopeptidase (NEP) inhibitor in combination with at least one another active agent optionally with other pharmaceutically acceptable excipients useful in the prophylaxis, treatment and/or amelioration of ...

Novel controlled release pharmaceutical compositions are provided which release the active agent(s) over an extended period of time comprising a core wherein the said core comprises at least one active agent(s) which is preferably water soluble, a lipid system comprising at least one lipid component(s), at least one...

Novel compositions particularly useful for the prophylaxis and/or amelioration and/or treatment of constipation and associated disorders comprising at least one bowel evacuant and a saccharide component optionally with at least one component selected from a group comprising antacid, antiflatulant, prokinetic, antisp...

The invention discloses the process of producing spray dried nanoparticles or microparticles of active agent and polymer without using high speed or high-pressure homogenization or ultra-sonification or micro-fluidization techniques. The process comprises the steps of (a) dissolving the active agent and polymer in f...

The present invention discloses compositions having particles comprising, inorganic element,; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixture thereo...

Novel injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hyd...

An antileukotriene, antihistaminic, antiallergic and anti-inflammatory composition of non-steroidal anti-inflammatory sulfonanilide (NSAID) or their pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof as active agent with second generation anti-histami...

An antileukotriene, antihistaminic, antiallergic and anti-inflammatory pharmaceutical composition is provided. More particularly the invention relates to a composition for use in allergic disorders namely rhinitis such as allergic rhinitis, acute and chronic rhinitis, seasonal allergic rhinitis; bronchitis, urticari...

Oral pharmaceutical compositions and process for preparing compositions comprising at least one gastric acid suppressing agent, at least one prokinetic agent and at least one alginic acid optionally with pharmaceutically acceptable excipients are provided; such that the gastric acid suppressing agent is present in a...

Provided in the present invention are novel spermicidal and anti-infective devices which are useful as a contraceptive method besides providing effective protection against microbes. Also provided are the process for preparation of such novel devices and method of using them. The novel devices of the present inventi...

Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a blend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizi...

Novel buccoadhesive compositions comprising at least one bioactive agent(s), at least one bioadhesive polymer(s), at least one water soluble sugar component(s) and at least one binder(s), optionally with other excipients are provided, wherein the said composition has improved cohesiveness, enhanced intactness and im...

Oral pharmaceutical compositions and process for preparation thereof are provided comprising at least one gastric acid suppressing agent, preferably a proton pump inhibitor or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs,, and one or more prokinetic agent or its pharmaceutica...

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmace...

The present invention relates to multilayered pharmaceutical compositions comprising at least one or more agents each selected from same or different classes having a low dose, comprising at least one polymer(s) or enteric polymer that predominantly controls or delays the release of at least one active agent(s) and ...

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formul...

Novel controlled release pharmaceutical compositions comprising at least one active agent(s), at least one pH dependent polymer(s), at least one pH independent preferably water soluble polymer(s), a channel forming agent(s), and optionally other pharmaceutically acceptable excipients are provided. Also described are...

Novel controlled release pharmaceutical compositions comprising at least one active agent(s), at least one hydrophilic component and at least one water insoluble component, optionally with at least one pH dependent polymer and/or other pharmaceutically acceptable excipient(s) are provided. Also described are process...

Novel low dose but therapeutically effective pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof, alongwith one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides proces...

Novel compositions comprising a combination of at least one higher primary aliphatic alcohol preferably selected from those having 18 to 40 carbon atoms or mixtures thereof, at least one source of 5-hydroxytryptophan (5-HTP) optionally additionally comprising a source of caffeine and/or catechin-polyphenol and/or ep...

Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzy...

The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolumus upon oral administration, the first amount of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate relea...

The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the system can be retained in the gastric region for a prolonged period of time. It comprises of a core, one or more layers coated over the core and a performed hollow spa...

The present invention provides a process of preparing amorphous/micronized nimesulide by spray drying method. Such process does not include the addition of pharmaceutically acceptable carriers such as solubilizer, stabilizer, polymer, salt, surfactant or alkali solution to increase the solubility of nimesulide. Nime...

The present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and compositions thereof. Particularly the recombinant fusion proteins of the present invention comprise the Edema factor protein (EF) preferably a native Edema factor protein (EF) or mutated Edema factor pr...

Oral pharmaceutical compositions comprising dry extract of Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of Euphorbia prostrata is not more than about 500 microns with pharmaceutical^ acceptable excipient(s) and process(s) for the preparatio...

The present invention provides an improved process for the synthesis of 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethanol intermediate, its derivatives and/or its pharmaceutically acceptable salts, useful in the synthesis of α-1 adrenoceptor blockers such as silodosin.

Novel modified release pharmaceutical composition comprising at least one active agent(s); a polymer system in an amount less than about 80% w/w of the composition comprising at least two swellable pH independent polymers wherein at least one is hydrophilic; optionally other pharmaceutically acceptable excipients is...

The present invention relates to novel compounds particularly compounds comprising benzazepine acetic acid derivatives chemically or physically linked to at least one another active agent to form a mutual prodrug and/or a mutual salt, process for preparation of such compounds and methods of using them. The presen...

Novel pharamaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, sovates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. Th...

Novel anti-inflammatory, antiallergic and/or antiasthmatic pharmaceutical compositions comprising at least one alkaloid component(s) derived from natural, semi-synthetic or synthetic source as active agent, either alone or in combination with other active agent(s), optionally with other pharmaceutically acceptable e...

Pharmaceutical compositions comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipooxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically acceptable excipients is provided. Also descr...

Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged durati...

The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. ...

An injectable anti-spasmodic composition comprising: Diclofenac or its salts or its chirally pure forms - From 1.0 to 10 % w/w Pitofenone hydrochloride - From 0.05 to 2.0 % w/w Fenpiverinium bromide - From 0.001 to 0.2 % w/w alongwith a vehicle and optionally one or more agents selected from pain reducers...

Provided are high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 360 mg to about 3000 mg preferably from about 400 mg to about 1600 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable exc...

An oral pharmaceutical composition comprising rifampicin and isoniazid, characterized in that the composition further comprises pH sensitive polymers selected from a group comprising of Cellulose Acetate Phthalate, Hydroxypropyl Methylcellulose Phthalate, Polyvinyl Acetate Phthalate, Hydroxypropyl Methylcellulose Ac...

Process for the preparation of a pharmaceutical composition of anti-tubercular drugs for oral use comprising treating Rifampicin and/or Isoniazid, in delayed release form or extended release form with pH senstive or pH independent polymers, as herein described, by conventional techniques and mixing the treated Rifam...

A process for the preparation of a homogenous substantially alcohol free composition of Cyclosporin which upon dilution witTi water, yields a stable, oil-in-water emulsion, whereof the oil phase consists of Cyclosporin containing globules having an average size of from 200 to 600 nm which comprises mixing 1-25 * w...

The present invention relates to a pharmaceutical composition of an oral therapeutically active, hitherto unexploited composition of an aliphatic amine polymers. More specifically this invention relates to pharmaceutical composition comprising carbonate salt of the aliphatic amine polymers such as sevelamer carbonat...

A novel fast dissolving pharmaceutical composition in solid dosage form with a prolonged sweet taste is provided which comprises at least one pharmaceutical active agent in an amount of from 0.1 to 99 weight % of the total dosage form; at least one water soluble sugar in an amount of from 5 to 95 weight % of the tot...

NA

A novel therapeutic analgesic pharmaceutical composition for intra-muscular administration is provided comprising 2.5% to 10% w/v of nimesulide and 90% to 97.5% w/v of parenteral absorption enhancing vehicle base, wherein said parenteral absorption enhancing base comprises 5% to 12% w/v of dimethylacetamide, 20% to ...

This invention relates to novel therapeutic anti-inflammatory and analgesic pharmaceutical compositions containing Nimesulide which is N- (4 nitro, 2 phenoxyphenyl methane sulphonamide) for use transdermally and a process for the manufacture thereof.

An oral anti-spasmodic composition comprising diclofenac or its salts as herein described from 6.188 to 61.88 % w/w, Pitofenone hydrochloride from 0.39 to 12.38 % w/w, Fenpiverinium bromide from 0.006 to 1.24 % w/w along with other pharmaceutical excipients is provided.

A novel composition for treating anorectal diseases and colonic diseases with long term effectiveness and low prolapse rates is disclosed. The composition comprises an extract of the plant Euphorbia prostrata containing one or more flavonoids in a pharmaceutical acceptable carrier(s)/base(s).

The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection again...

A novel homogenous alcohol free, free flowing, clear and transparent pharmaceutical composition containing Cyclosporin is disclosed. The amount of Cyclosporin is easily measurable at a wide range of temperature of 15° to 45°C. The composition comprises a Cyclosporin in a hydrophillic carrier medium comprising propyl...

The present invention discloses a homogenous alcohol-free, transparent composition comprising a Cyclosporin in a hydrophilic carrier medium and process of preparing such composition. The said hydrophilic carrier medium comprises propylene glycol and polyoxyethylene hydrogenated castor oils additionally with a transe...

The composition in accordance with present invention comprises a controlled release pharmaceutical composition of Nimesulide which comprises nimesulide as an active drug from 5% to 95% w/w of the composition one or more sustaining materials from 2% to 95% w/w of the composition and pharmaceutical excipients from 0% ...

A novel phanuacatical composition in the form of a tablet consisting of Cetirizine in taste masked form admixed with a fast dissolving matrix comprising; sugar alcohol(s), sweetener(s), binder(s), super disintegrant(s), flavouring agent(s), electrolyte(s), acidifying agent(s) and lubricant(s)/ glidants(s) is p...

A novel homogenous alcohol free, free flowing, clear and transparent pharmaceutical composition containing Cyclosporin is disclosed. The amount of Cyclosporin is easily measurable at a wide range of temperature of 15° to 45°C. The composition comprises a Cyclosporin in a hydrophilic carrier medium comprising proplyl...

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-alpha) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF -...

The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula ...

A Parenteral Water-miscible non-intensely colored injectable composition of Non-steroidal anti-inflammatory drugs is disclosed. The invention utilizes solubilization techniques to achieve sufficiently high concentrations of Nimesulide suitable to deliver therapeutic doses in conveniently small volumes using water an...

The invention describes a homogenous alcohol free composition of Cyclosporin in a hydrophilic carrier medium comprising propylene glycol, esters of propylene glycol with C4 to C12 fatty acids and polyoxyethylene hydrogenated castor oils.

The present invention relates to a targeted vesicular composition for treatment of H. pylori infections and for cytoprotection.

A controlled release solid pharmaceutical composition of nimesulide is provided which comprises nimesulide as an active drug from 5% to 95% w/w, one or more sustaining materials from 2% to 95% w/w of the composition and pharmaceutical excipients from 0% to 90% w/w of the composition selected from a group comprising ...

The present invention provides an improved antimicrobial and spermicidal composition comprising 1 to 40% by weight of said composition of Praneem, 0.01 to 10% by weight of said composition of purified saponins obtained from Sapindus mukorossi. from 0.01 to 20% by weight of said composition of Mentha citrata oil and ...

Novel effervescent pharmaceutical compositions comprising Nimesulide, characterized in that the said pharmaceutical composition further comprises one or more acids from 5% to 90% w/w of the composition and one or more carbonate sources from 5% to 90% w/w of the composition with one or more pharmaceutical aids select...

The present invention relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acceptable salts and derivatives thereof. The present invention further relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acc...

The present invention relates to novel compounds of formula 1. their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs. metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Fo...

Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in-vitro dissolutio...

A controlled release composition comprising N-(4-nitro-2-phenoxyphenyl) methanesulfonamide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present...

The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effecti...

A component vaccine against pertussis obtaining Pertactin (PRN) antigen from Bordetella Pertussis. A simplified process for extraction and purification of Pertactin (PRN). Pertactin obtained by this method has a purity level of more than 90% and the process used in the present invention prevents the loss of PRN by a...

Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) ...

The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, whole cell pertussis and polio. The present invention also relates to inclusion of one or more antigens in the said combination vaccine, for protection against infectio...

The present invention relates to novel recombinant plasmids comprising a cassette of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV) wherein the said genes are inserted at a nonessential site preferably Del III, within the modifie...

The present invention relates to novel and improved multivalent pneumococcal vaccines, wherein polysaccharides from different S. pneumoniae serotypes are conjugated to at least 2 or more carrier proteins selected from a group comprising diphtheria toxin, diphtheria toxoid, CRM 197, tetanus toxoid, pertussis toxoid, ...

The present invention is related to the field of synthetic chemistry. It is related to process of synthesis of Azilsartan Medoxomil and its pharmaceutically acceptable salts. The present invention also relates to intermediates useful in the preparation of Azilsartan Medoxomil.

The present invention is related to a novel process of synthesis of (2a,5(3,7p,10(3,13a)-4-acetoxy-13-({(2R,3S)-3[(tert-butoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate (Cabazitaxel) and its pharmaceutically acceptable salts. The present inventi...

A therapeutic composition for the treatment of migraine and process for preparing such composition is provided. The composition comprises a 5HTiD receptor agonist as herein described from 0.05 to 85% w/w and nimesulide and salts thereof from 0.05 to 85% w/w of the composition along with other conventional ingredient...

A composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and nicotinic acid, its salts or derivatives thereof optionally with excipients, a...

Novel pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of t...

The invention relates to a composition and method for producing an anti-androgenic effect in a mammal. The composition is a modified release pharmaceutical composition is a modified release pharmaceutical composition of bicalutamide, a non-steroidal anti-androgen, which can be administered with a reduced dosing freq...

Provided in the present invention is an improved, environment friendly and industrially viable process for the preparation of substituted benzopyran imidazolidine diones preferably 2-substituted-6-substituted-2,3-dihydrospiro-[4H-l-benzopyran-4,4"-imidazolidine]-2,5'-diones represented by formula-I as described here...

The present invention describes novel pharmaceutical compositions for oral administration comprising eplerenone as an active agent or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally with one or more pharmaceutically accep...

Novel extended release pharmaceutical compositions are provided comprising a core, wherein the core comprises a water soluble active agent which is venlafaxine or alfuzosin or pramipexole or rivastigmine, or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enant...

Novel injectable depot compositions are provided comprising at least one active agent(s) optionally with one or more pharmaceutically acceptable excipient(s) in the form of a multi-component system preferably comprising at least two components which when administered to a subject in need thereof forms an in situ gel...

The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating can...

The present invention relates to novel process for purification of influenza viruses and the highly pure influenza virus obtained by such process. The invention is based on the premise that specific modification of viral purification processes can lead to increases in the yield, purity and robustness. The invention ...

The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating can...

Novel therapeutic anti-inflammatory and analgesic pharmaceutical composition for topical/transdermal use and process for preparing such compositions are provided. The composition comprises a selective COX-2 inhibitor drug from 0.1% to 40% w/w and percutaneous absorption enhancing vehicle/base from 60% to 99....

Novel multivalent vaccine formulation comprising sabin strain derived inactivated polio vaccine containing one or more types of polio viruses absorbed on an adjuvant alongwith a number 'n' of one or more other antigen(s) absorbed on an adjuvant, wherein the value of 'n' is between 1 to 10 is described....

A novel topical composition having a unique combination of ingredients, and weight percentages thereof, for use as effective carrier vehicles for one or a plurality of active agents such as NASAIDs that is to be applied topically to the skin of a human being or animal. The present ihvention specifically relates to A...

The present invention relates to novel Streptococcus pneumoniae immunogenic compositions, method of preparing such a single injection/ administration/ immunization in providing active immunization for protection against pneumonia, hepatitis and additionally against infections including tetanus, diphtheria, pertussis...

The present disclosure relates to a novel improved multivalent pneumococcal vaccine compositions comprising up to 30 capsular pneumococcal polysaccharide of Streptococcus pneumoniae serotypes conjugated to two or more carrier proteins. Usually incorporating multiple antigens in the vaccine composition also increases...

A process for the preparation of controlled release pharmaceutical composition containing Nimesulicle as an active drug which comprises mixing Nimesulide upto 99 % w/w, one or more release control sustaining materials from 0.1 to 99 % w/w. Pharmaceutical excipients from 0 % to 90 % w/w and optionally ad...

Process for the preparation of Polio Vaccine derived from Sabin strain for immunization against poliomyelitis which comprises of preparing Polio Vaccine from Sabin seed strain or Sabin strain monovalent bulk suspensions used for blending of trivalent Oral Polio Vaccine or by growing Sabin strain polio...

The present invention relates to field of novel improved stable recombinant adenovirus compositions comprising recombinant adenovirus vector/s and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such stable composition comprising recombina...

The present invention relates to a multi valent vaccine composition comprising antigens against Diphtheria toxoid (DT), Tetanus toxoid (TT), Whole-cell pertussis (wP)/ Acellular Pertussis ( aP), Polio/ Inactivated Poliomyelitis (IPV), Hepatitis (Hep) and Haemophilus influenzae (Hib) wherein Haemophilus influenza...